Navigation Links
Uroplasty Reports Third Quarter Fiscal 2009 Results
Date:2/3/2009

actual results to differ materially from our anticipated results. We discuss in detail the factors that may effect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. Further, we cannot assure you that our SUmiT clinical trial will produce favorable results, that even if it does produce favorable result third-party payors will provide or continue to provide coverage and reimbursement, or reimburse the providers an amount sufficient to cover their costs and expenses, or that we will timely obtain, or even succeed at all at obtaining, a specific "listed" CPT reimbursement code from the AMA for Urgent PC treatments. We further cannot assure that reimbursement or other issues will not further impact our fiscal 2009 results.

     For Further Information: Uroplasty, Inc.           EVC Group
     David Kaysen, President and CEO, or                Doug Sherk (Investors)
     Medi Jiwani, Vice President, CFO, and Treasurer,   415.896.6820
     952.426.6140                                       Chris Gale (Media)
                                                        646.201.5431



                       UROPLASTY, INC. AND SUBSIDIARIES

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)

                            Three Months Ended       Nine Months Ended
                               December 31,              December 31,
                            2008         2007         2008         2007

    Net sales           $3,387,285   $3,729,314  $11,833,422   $9,717,531
    Cost of goods sold     533,987      789,955    1,791,153    2,053,208

    Gross profit         2,853,298    2,939,359   10,042,269    7,664,323

    Operating expenses
      General and
       administrative      713,545      799,193    2,670,653    2,755,000
      Research and
       development         723,673      460,374    1,457,170    
'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York
2. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
3. Uroplasty to Host Third Quarter Conference Call on February 11
4. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
6. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
7. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
8. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
9. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
10. Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
11. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased to ... in Charlottetown , PEI.  Bioenterprise has ... Island ADAPT Council for the commercialization of agricultural technologies ... working with PEI ADAPT.  They have been at the ... a decade," explains Dave Smardon , President & ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... - Last week, the nation marked the five-year ... research. Those restrictions have unquestionably set back the progress ... , ,When Congress passed legislation that would have lifted ... whose loved ones are suffering from a wide range ...
... After months of speculation, North Prairie Productions, LLC , ... site for a biodiesel plant that will produce 45 million ... construction on the $42 million facility next spring on about ... it will relocate its Waterloo offices. , ,The site ...
... of Lucigen Corp. will receive two prominent visitors on ... grants. , ,C5-6, which will produce enzymes for use in ... of the Bio-Based Industry Initiative of Wisconsin Gov. ... which is part of $1 million in new state funding for ...
Cached Biology Technology:Stem cell research holds the promise for tomorrow 2Stem cell research holds the promise for tomorrow 3Evansville site chosen for biodiesel plant 2Madison business receives $115,000 of new state biofuels funding 2
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... first study to ever explore biological activity in the deepest ... range of capabilities, including eating hydrocarbons and natural gas, and ... the journal PLoS One, showed that a significant ... temperatures near the boiling point of water. "This is ...
... is available in German . , For the first ... cells in order to study them. Instead, whole living cells are ... an immediate 3-D image, thereby closing a gap between conventional microscopic ... the entire cell in one step. This is an advantage over ...
... International businessman and philanthropist Foster Friess has donated $50,000 to ... ovary (SCCO) by the Translational Genomics Research Institute (TGen) and ... donation in memory of Taryn Ritchey, 22, who in 2007 ... strikes women in the prime of life. "Taryn,s dying ...
Cached Biology News:Busy microbial world discovered in deepest ocean crust ever explored 2New microscope reveals ultrastructure of cells 2Businessman-philanthropist assists TGen-VARI study of rare cancer 2Businessman-philanthropist assists TGen-VARI study of rare cancer 3
... For the professional, student, or faculty researcher, the ... accelerate your research and improve the quality of ... is the edge that researchers using LI-COR DNA ... years. The 4300 System is a third generation ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Ideal for biocompatibility testing at various ... of air through a clean heating ... temperature up to 140F. Transparent panels ... shields allow easy access to the ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Biology Products: